Journal article
Assessment of the Electronic Retinal Implant Alpha AMS in Restoring Vision to Blind Patients with End-Stage Retinitis Pigmentosa
TL Edwards, CL Cottriall, K Xue, MP Simunovic, JD Ramsden, E Zrenner, RE MacLaren
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Purpose: To report the initial efficacy results of the Retina Implant Alpha AMS (Retina Implant AG, Reutlingen, Germany) for partial restoration of vision in end-stage retinitis pigmentosa (RP). Design: Prospective, single-arm, investigator-sponsored interventional clinical trial. Within-participant control comprising residual vision with the retinal implant switched ON versus OFF in the implanted eye. Participants: The Retina Implant Alpha AMS was implanted into the worse-seeing eye of 6 participants with end-stage RP and no useful perception of light vision. Eligibility criteria included previous normal vision for ≥12 years and no significant ocular or systemic comorbidity. Methods: Vision..
View full abstractGrants
Funding Acknowledgements
The author(s) have made the following disclosure(s): E.Z.: Grants, personal fees, nonfinancial support, and other - Retina Implant AG, Kusterdingen, Germany; Grants - Tistou and Charlotte Kerstan Foundation; Grants - German Research Council (EXC 307), during the conduct of the study. In addition, E.Z. has a patent on Subretinal Implant Technology issued and a patent on Retina Implant concepts pending.Financial support was received from the Invention for Innovation Award, National Institute for Health Research, United Kingdom; Oxford University Hospitals NHS Foundation Trust Biomedical Research Centre; and Nuffield Medical Fellowship. E.Z. was supported by the German Research Council Excellence Cluster 307 (Centre of Integrated Neuroscience), Retina Implant AG, and the Tistou and Charlotte Kerstan Foundation.